RecruitingPhase 2NCT07654283

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B in the North America and Europe Regions

Sponsor

AusperBio Therapeutics Inc.

Enrollment

70 participants

Start Date

Aug 27, 2026

Study Type

INTERVENTIONAL

Conditions

Hepatitis B, Chronic

Summary

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AHB-137 for people with hepatitis b, chronic. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAHB-137

Subcutaneous injection

Locations(10)

Stanford University

Palo Alto, California, United States

University of Maryland

Baltimore, Maryland, United States

NYU Langone Health

New York, New York, United States

Texas Liver Institute

San Antonio, Texas, United States

University of Calgary

Calgary, Alberta, Canada

Toronto General Hospital

Toronto, Ontario, Canada

Hôpital Beaujon

Clichy, France

Clinica Mangiagalli

Milan, Milan, Italy

Vall d'Hebron Hospital

Barcelona, Barcelona, Spain

King's College Hospital

London, London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07654283

Related Trials

Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region

NCT073702078 locations

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

NCT066802324 locations

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

NCT06923280

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

NCT074918482 locations

Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

NCT062164701 location